KCT0000804
Completed
未知
Development of antiplatelet therapy protocol for coil embolization of intracranial aneurysm
ConditionsDiseases of the nervous system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the nervous system
- Sponsor
- Seoul National University Bundang Hospital
- Enrollment
- 290
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Standard vs modified antiplatelet preparation
- •1\. Patients with intracranial aneurysm who plan to undergo coil embolization
- •2\. Patient aged 20 years and more at the day of enrollment
- •3\. Patient with less than 2 of modified Rankin scale score at the day of enrollment
- •4\. Patient who agrees and writes out a consent form
- •Short vs long\-term dual antiplatelet therapy
- •1\. Patients with unruptured aneurysm treated with stent\-assisted coiling within 30 days at the day of enrollment
- •2\. Patient aged 20 years or more at the day of enrollment
- •3\. Patient who agrees and writes out a consent form
Exclusion Criteria
- •Standard vs modified antiplatelet preparation
- •1\. Patient with histoy of hypersensitivity of aspirin, clopidogrel, cilostazol, or prasugrel
- •2\. Patient with high possibility of active bleeding such as symptomatic intrcranial hemorrhage or active gastric ulcer
- •3\. Patient with bleeding tendency or coagulopathy
- •4\. Patient with thrombocytopenia (\< 100,000/mm3 of platelet count within three months before enrollment)
- •5\. Patient with liver disease (\> 100 of AST or ALT within three months before enrollment)
- •6\. Patient with renal disease (\> 2mg/dL of serum creatinin within three months before enrollment)
- •7\. Patient using anticoagulants
- •8\. Patients with congestive heart failure or angina unable to be controlled
- •9\. Patients with malignant tumor requiring treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Controlled Anti-platelet medical therapy based on rapid CYP2C19 gene evaluation in Acute myocardial infarctioAcute myocardial infarctionJPRN-UMIN000008151Graduate School of Medical Sciences, Kumamoto University100
Completed
Phase 4
Antiplatelet therapy for patients undergoing transcatheter aortic valve implantatioNL-OMON45158Sint Antonius Ziekenhuis500
Active, not recruiting
Phase 1
Antiplatelet therapy for patients undergoing transcatheter aortic valve implantatioAortic stenosis for which a transcatheter aortic valve implantation (TAVI) is performed.MedDRA version: 19.1Level: PTClassification code 10002906Term: Aortic stenosisSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2013-003125-28-GBSt. Antonius Hospital1,000
Recruiting
Not Applicable
Antiplatelet therapy for patients undergoing transcatheter aortic valve implantatioAortic valve diseaseaortic valve stenosisbleedingstrokethrombosisplatelet inhibitors.NL-OMON25546St Antonius Hospital, Nieuwegein, the Netherlands1,000
Active, not recruiting
Phase 1
Antiplatelet therapy for patients undergoing transcatheter aortic valve implantatioEUCTR2013-003125-28-BESt. Antonius Hospital1,000